Document Detail


Pulmonary hypertension in left heart disease.
MedLine Citation:
PMID:  23204122     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pulmonary hypertension (PH) is a frequent complication of left heart disease arising from a wide range of cardiac disorders. In the clinical classification, PH associated with left heart disease is classified as Group 2, which includes left heart systolic dysfunction, left heart diastolic dysfunction and left heart valvular disease. In the past, rheumatic mitral valve disease was the most common cause of PH in left heart disease; however, today it is more likely to be associated with hypertensive and/or ischaemic heart disease. As the incidence of these conditions is increasing, the number of patients presenting with PH is also increasing and, today, left heart disease represents the most frequent cause of PH. The development of PH in patients with left heart disease is associated with poor prognosis. However, despite the increasingly large number of patients affected and the impact of PH on outcome, there are currently no specific treatment options for these patients. This review gives an overview of the pathophysiology and epidemiology of PH associated with left heart disease, and discusses the challenges associated with its management and treatment.
Authors:
Marco Guazzi; Nazzareno Galiè
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  European respiratory review : an official journal of the European Respiratory Society     Volume:  21     ISSN:  1600-0617     ISO Abbreviation:  Eur Respir Rev     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-03     Completed Date:  2013-05-24     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  9111391     Medline TA:  Eur Respir Rev     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  338-46     Citation Subset:  IM    
Affiliation:
Heart Failure Unit, University of Milan, IRCCS Policlinico San Donato, Milan. marco.guazzi@unimi.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antihypertensive Agents / therapeutic use
Echocardiography, Doppler
Electrocardiography
Endothelin-1 / metabolism
Endothelium, Vascular / metabolism,  physiopathology
Exercise Test
Heart Valve Prosthesis
Humans
Hypertension, Pulmonary / diagnosis,  epidemiology,  physiopathology*,  therapy
Mitral Valve / surgery
Nitric Oxide / metabolism
Phosphodiesterase 5 Inhibitors / therapeutic use
Pulmonary Wedge Pressure
Radiography, Thoracic
Receptor, Endothelin A / antagonists & inhibitors
Stroke Volume / physiology
Sulfonamides / therapeutic use
Vascular Resistance / physiology
Vasodilator Agents / therapeutic use
Ventricular Dysfunction, Left / diagnosis,  epidemiology,  physiopathology*,  therapy
Weight Loss
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Endothelin-1; 0/Phosphodiesterase 5 Inhibitors; 0/Receptor, Endothelin A; 0/Sulfonamides; 0/Vasodilator Agents; 10102-43-9/Nitric Oxide; Q326023R30/bosentan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pulmonary arterial hypertension associated with congenital heart disease.
Next Document:  Palliative care in COPD patients: is it only an end-of-life issue?